D.E. Shaw & Co
BHVN

D.E. Shaw & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

D.E. Shaw & Co’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,900
Closed -$3.25M – 4710
2020
Q4 		$3.25M Sell
37,900
-2,100
-5% -$178K ﹤0.01% 2209
2020
Q3 		$2.6M Hold
40,000
– – ﹤0.01% 2201
2020
Q2 		$2.92M Hold
40,000
– – ﹤0.01% 2101
2020
Q1 		$1.36M Hold
40,000
– – ﹤0.01% 2490
2019
Q4 		$2.18M Buy
40,000
+10,000
+33% +$495K ﹤0.01% 2397
2019
Q3 		$1.25M Hold
30,000
– – ﹤0.01% 2701
2019
Q2 		$1.31M Buy
+30,000
New +$1.69M ﹤0.01% 2512

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

D.E. Shaw & Co's BHVN Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 101,674 shares — an estimated $15.4M sold.

D.E. Shaw & Co first reported a position in BHVN in Q1 2019 and held it in 15 quarters. The position peaked at $33.3M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • D.E. Shaw & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 101,674 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $15.4M.
  • D.E. Shaw & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 15 quarters.
  • D.E. Shaw & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33.3M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.